| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
From the Department of Pathology,*
Brigham and Women's
Hospital and Harvard Medical School, and Department of Adult
Oncology,
Dana-Farber Cancer Institute,
Department of Medicine, Harvard Medical School, Boston, Massachusetts
The 150-kd transmembrane protein CD100 is the first semaphorin protein shown to be expressed in lymphoid tissue. CD100 is present in the interfollicular T cell zones and is also expressed by B cells in the germinal centers of secondary lymphoid follicles, but not in the mantle zones. The CD100 molecule was recently cloned, and CD100 transfectants were shown to induce homotypic aggregation of human B cells and improve their viability in vitro, suggesting that CD100 may play a role in lymphocyte aggregation and germinal center formation. We studied the expression of CD100 in 138 clinical cases representing a range of lymphoproliferative disorders, to determine whether this molecule is expressed in these neoplastic processes. In general, we found CD100 expression to be common in peripheral T-cell non-Hodgkin's lymphomas but rare in B-cell non-Hodgkin's lymphomas. CD100 expression was not detectable in low-grade B-cell non-Hodgkin's lymphomas, including cases of small lymphocytic lymphoma (18 cases), marginal zone lymphoma (10 cases), and mantle cell lymphoma (10 cases), as might be expected for these neoplasms that are not of follicular center cell origin. Surprisingly, we found that the vast majority of follicular lymphomas (37 of 40 cases) as well as diffuse large-cell lymphomas of B-cell type (35 cases) did not express CD100. The neoplastic cells in 3 of 11 cases of predominantly large-cell-type follicular lymphoma did express CD100. In contrast, all five cases of high-grade, small non-cleaved (Burkitt-like) B-cell lymphoma were immunoreactive for CD100 expression, as were 18 of 20 cases (90%) of malignant T cell neoplasms. Northern blot analysis of CD100 expression correlated with immunohistochemical findings. Absence of expression of CD100 by neoplastic follicular center B cells is a common feature in follicular lymphomas, but expression of CD100 by T cells is maintained in T-cell lymphoproliferative disorders.
This article has been cited by other articles:
 |
|
 |
|
  J. A. Brown, D. M. Dorfman, F.-R. Ma, E. L. Sullivan, O. Munoz, C. R. Wood, E. A. Greenfield, and G. J. Freeman Blockade of Programmed Death-1 Ligands on Dendritic Cells Enhances T Cell Activation and Cytokine Production J. Immunol., February 1, 2003; 170(3): 1257 - 1266. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Jones, C. O'Hara, M. D. Kraus, A. R. Perez-Atayde, A. Shahsafaei, L. Wu, and D. M. Dorfman Expression pattern of T-cell-associated chemokine receptors and their chemokines correlates with specific subtypes of T-cell non-Hodgkin lymphoma Blood, July 15, 2000; 96(2): 685 - 690. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Brambilla, B. Constantin, H. Drabkin, and J. Roche Semaphorin SEMA3F Localization in Malignant Human Lung and Cell Lines : A Suggested Role in Cell Adhesion and Cell Migration Am. J. Pathol., March 1, 2000; 156(3): 939 - 950. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Billard, S. Delaire, E. Raffoux, A. Bensussan, and L. Boumsell Switch in the protein tyrosine phosphatase associated with human CD100 semaphorin at terminal B-cell differentiation stage Blood, February 1, 2000; 95(3): 965 - 972. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Jones, R. J. Benjamin, A. Shahsafaei, and D. M. Dorfman The chemokine receptor CXCR3 is expressed in a subset of B-cell lymphomas and is a marker of B-cell chronic lymphocytic leukemia Blood, January 15, 2000; 95(2): 627 - 632. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
